Interrogate COVID-19 with Tecan’s SARS-CoV-2 S1/RBD IgG Ab ELISA

Boost throughput of your antibody testing to help the fight against the pandemic.

Serological testing of IgG antibodies directed against SARS-CoV-2 plays an essential role in determining the prevalence of the virus. Efficient immune status monitoring can be used for prescreening of individuals before vaccination, as well as for investigating post-vaccination responses*. Serological tests are not intended to determine the presence of the virus, but to detect an immune response by the body, supplementing methods that provide additional information on direct virus detection (eg. PCR testing).

Tecan’s SARS-CoV-2 S1/RBD IgG Ab ELISA is a quantitative test detecting IgG antibodies directed against the SARS-CoV-2-S1 spike protein’s receptor binding domain (RBD), which helps to determine immune status.

Main benefits of Tecan SARS-CoV-2 IgG Ab ELISA:

  • Specific results from spike protein antigen (S1/RBD)
  • Excellent performance: 100 % sensitivity and 99.3 % specificity
  • Detects analyte in just 10 µL sample volumes
  • Minimal incubation times of less than 3 hours
  • Ready to use, with positive and negative controls included
  • Can be used manually or automated on open format ELISA processors**
WidgetTarget_01

* Jääskeläinen AJ, et al. Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples. Eurosurveillance, 2020, 25(18), 2000603.

** The combined use of assay, process script and instrument must be validated individually on site by each laboratory.

The Tecan SARS-CoV-2 S1/RBD IgG ELISA is CE-IVD marked in Europe, and may not be available in all countries. Please contact your local Tecan office.

You can download the product sheet here.